Early Access — free while we kick the tires
Joachimczyk Paul
CFO
Officer
Latest: SONOCO PRODUCTS CO CFO buying · April 2026
2 filings analyzed
·
1 company
·
Latest 2026-04-24
Never miss a filing from Joachimczyk Paul
Watch this insider and we'll alert you the moment they file — at any company.
Companies
| Company |
Buys |
Sells |
Direction |
Holdings |
Latest |
|
SONOCO PRODUCTS CO
SON
|
2 |
0 |
Net buying
|
36,906
|
2026-04-24
|
Activity
April 2026
CFO Paul Joachimczyk purchased 8,058 shares of SON at $49.64; stock down 15.9% from 52-week high, up 41.7% in annual revenue.
CFO Paul Joachimczyk bought 8,058 shares at $49.64 on 2026-04-24, increasing his holdings from 20,500 to 28,558 shares (+39.3%). The purchase represents a material commitment at a time when the stock trades 15.9% below its 52-week high and 9.3% lower over the prior 30 days. Joachimczyk's prior trading history at SON shows 5 consecutive buys all executed on 2025-10-29, each returning approximately 6.8–6.9% over 30 days and 21.8–22.0% over 90 days—a 100% win rate at this ticker. The company's fundamentals remain solid: annual revenue growth of 41.7%, a P/E of 3.26, and recent quarterly revenue of $2.1B. This purchase occurs against a backdrop of recent price weakness but aligned with Joachimczyk's demonstrated pattern of advantageous entry timing at SON over the prior six months.
October 2025
CFO Paul Joachimczyk purchases 20,500 shares at blended avg $39.50, accumulating $809,746.23 position in SON.
Joachimczyk executed 5 separate purchases totaling 20,500 shares for $809,746.23 at an average price of $39.50 on 2025-10-29, establishing his first recorded shareholding in Sonoco Products. The transaction occurs with the stock at $39.27, down 26.3% from its 52-week high of $53.27 and down 8.9% over the prior 30 days. Sonoco's fundamentals show annual revenue contracted 23.2% year-over-year to $2.1B (latest quarter), though the company maintains a low P/E of 6.16 with $122.9M net income. The large, structured purchase by the CFO during a period of significant price weakness and revenue contraction warrants monitoring to understand whether this reflects confidence in near-term operational recovery or reflects other strategic considerations.